Avanir on track to resubmit Zenvia on positive pseudobulbar extension data
This article was originally published in Scrip
Executive Summary
A reformulated version of Avanir's Zenvia (dextromethorphan plus quinidine) is safe and effective for the treatment of pseudobulbar affect (PBA), show open-label extension data from the STAR Phase III trial.